<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01963793</url>
  </required_header>
  <id_info>
    <org_study_id>LP0066-1019</org_study_id>
    <nct_id>NCT01963793</nct_id>
  </id_info>
  <brief_title>Topical Aprepitant in Prurigo Patients</brief_title>
  <acronym>iTAPP</acronym>
  <official_title>Topical Aprepitant in Prurigo Patients An Exploratory Phase IIa Trial With Topically Applied Aprepitant in Patients With Prurigo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Topical Aprepitant in Prurigo Patients - An Exploratory Phase IIa Trial With Topically
      Applied Aprepitant in Patients With Prurigo
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy of topical aprepitant treatment</measure>
    <time_frame>4 weeks</time_frame>
    <description>To investigate the efficacy of topical treatment with aprepitant on pruritus compared to placebo, after 4 weeks of treatment using VAS (Visual Analogue Score)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>efficacy of topical applied aprepitant</measure>
    <time_frame>4 weeks</time_frame>
    <description>To assess efficacy of topical applied aprepitant on the status of the skin condition compared to placebo, after 4 weeks of treatment using patient global assessment and clinical score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>long-term effect of topical applied aprepitant</measure>
    <time_frame>6 weeks</time_frame>
    <description>To assess long-term effect (e.g., duration of action, duration of reduction of pruritus) of topical applied aprepitant in comparison to placebo, after a follow up period of 2 weeks at the end of the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect of topical applied aprepitant on skin structures</measure>
    <time_frame>4 weeks</time_frame>
    <description>To assess effect of topical applied aprepitant on skin structures in comparison to placebo, after 4 weeks of treatment using TEWL (Transepidermal Water Loss)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pruritus</condition>
  <arm_group>
    <arm_group_label>placebo (left) / aprepitant (right)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>placebo (on defined treatment area on left side of the body) / aprepitant (on defined treatment area on right side of the body)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aprepitant (left) / placebo (right)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>aprepitant (on a treatment area on the left side of the body) / placebo (on a treatment area on the right side of the body)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <description>Aprepitant gel (10 mg/g)</description>
    <arm_group_label>placebo (left) / aprepitant (right)</arm_group_label>
    <arm_group_label>aprepitant (left) / placebo (right)</arm_group_label>
    <other_name>Aprepitant gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>gel without active component</description>
    <arm_group_label>placebo (left) / aprepitant (right)</arm_group_label>
    <arm_group_label>aprepitant (left) / placebo (right)</arm_group_label>
    <other_name>aprepitant gel vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with Prurigo suffering from chronic pruritus

          -  Disease duration &gt; six month

          -  Therapy refractory to at least two previous antipruritic treatments with topical,
             intralesional or systemic corticosteroids, or other immunosuppressants,
             antihistamines, antipsychotics, antidepressants, anticonvulsants and/or UV-irradiation

          -  Adult male or female patients, aged 18 to 80 years

        Exclusion Criteria:

          -  Concomitant medications that are primarily metabolized through Cytochrome P450 3A4

          -  Applied topical antihistamines, corticosteroids or mast cell stabilizers to the skin
             less than 3 weeks prior to Visit 1 (Screening) or during the course of the trial

          -  UV-irradiation during the last 6 weeks prior to Visit 1 (Screening)

          -  Prescribed systemic medications are limited

          -  Clinically significant abnormalities in Blood analyses

          -  Anamnestic excessive use of alcohol or tobacco or drugs

          -  Presence of active tumor disease or history of malignancies within five years prior to
             Visit 1 (Screening)

          -  Known or suspected hypersensitivity to component(s) of investigational products

          -  Within the last 30 days or current participation in any other interventional clinical
             trial

          -  Subjects who have received treatment with any non-marketed drug substance (i.e., an
             agent which has not yet been made available for clinical use following registration)
             within the last 6 month

          -  Previously enrolled/randomised in this clinical trial

          -  In the opinion of the investigator, the subject is unlikely to comply with the
             Clinical Study Protocol (e.g., alcoholism, drug dependency or psychotic state)

          -  Females who are pregnant, of child-bearing potential and wishing to become pregnant
             during the trial or are breast feeding

          -  Females of child-bearing potential with positive pregnancy test

          -  Subjects (or their partner) not using an adequate method of contraception (according
             to national requirements, as applicable)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurer (ICI) Marcus, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allergie-Centrum-Charité, Charité Universitätsmedizin Berlin, Charitéplatz1, D-10117 Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergie-Zentrum-Charité, Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>D-10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2013</study_first_submitted>
  <study_first_submitted_qc>October 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2013</study_first_posted>
  <last_update_submitted>October 6, 2014</last_update_submitted>
  <last_update_submitted_qc>October 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pruritus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
    <mesh_term>Prurigo</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

